CTRI/2013/06/003713已完成未知
An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany and Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany in healthy, adult, human subjects, under fasting conditions - Not Applicable
Dushen J Chetty PhD0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •â??Healthy human subjects within the age range of 18 to 45 years (both inclusive)
- •â??Non-smokers since at least six months
- •â??Willingness to provide written informed consent to participate in the study
- •â??Body-mass index (BMI) of ï?³ 18.5 kg/m2 and ï?£ 24.9 kg/m2, with body weight not less than 50 kg
- •â??Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
- •â??Normal 12-lead ECG or one with abnormality considered to be clinically insignificant
- •â??Normal chest X-ray PA view
- •â??Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol.
- •â??Female Subjects
- •of child bearing potential practicing an acceptable method of birth control while in the study and for 14 days after the end of the study, as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence, or
- •post-menopausal for at least 1 year, or
- •surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject
- •â??Male Subjects
- •Willing to use an approved form of birth control (a double barrier method like condom with spermicide or condom with diaphragm) while in the study and for 14 days after the end of the study, and agree not to donate sperm during this period
排除标准
- •â??Personal / family history/ past history of allergy or hypersensitivity to ASA or pantoprazole or related drugs.
- •â??Any contraindication to anticoagulant therapy
- •â??History of sensitivity to heparin or heparin-induced thrombocytopenia
- •â??Past history of active gastric or duodenal ulcer or esophagitis
- •â??A history of cholecystectomy or biliary tract disease including increased liver function tests of known or unknown etiology
- •â??Subjects who have been diagnosed with Gilbertâ??s syndrome (Elevated LFTâ??s (SGOT/SGPT) + Bilirubin (total and direct))
- •â??Past history of anaphylaxis or angioedema
- •â??Any history of myopathy
- •â??Female subject not willing to use acceptable method of contraception from the date of screening until 14 days after the end of the study
- •â??Male subject not willing to use acceptable method of contraception from the date of screening until 14 days after the end of the study
- •â??Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g.congestive heart failure, hepatitis, pancreatitis etc.
- •â??Presence of any clinically significant abnormal values during screening e.g. significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test (RFT) etc.
- •â??Any cardiac, renal or liver impairment, any other organ or system impairment
- •â??History of seizure or psychiatric disorders
- •â??Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus
- •â??History of significant alcohol consumption for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to check-in in each period and during the study [one drink is equal to one unit of alcohol [one glass wine, half pint beer, and one measure (one ounce) of spirit].
- •â??Presence of painful erythema, oedema, or ulceration in the oral cavity
- •â??Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period
- •â??Use of any recreational drug or a history of drug addiction
- •â??Participation in any clinical trial within the past 3 months
- •â??Inaccessibility of veins in left and right arm
- •â??Donation of blood (one unit or 330 mL) within 3 months prior to study check-in
- •â??History of use of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to study check-in or repeated use of drugs within the last four weeks
- •â??History of unusual diet, for whatever reason , e.g. low sodium diet, for 7 days prior to check-in for all the three periods
- •â??History of consumption of grapefruit-containing food or drinks within 7 days prior to the study check-in for all the three periods
- •â??Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 7 days prior to the study check-in for all the three periods
- •â??Difficulty in swallowing solids like tablets/capsules
- •â??Systolic blood pressure below 100 mm Hg and above 138 mm Hg, diastolic blood pressure below 60 mm Hg and above 90 mmHg
- •â??Heart rate below 60 beats/minute and above 100 beats/minute
- •â??Temperature below 96.00 F and above 98.60 F
- •â??Female volunteers demonstrating a positive test for pregnancy during screening or currently breast-feeding
研究者
相似试验
尚未招募
1 期
Relative bioavailability study of two different beaches of Metformin Hydrochloride Prolonged Release Tablets 1000 mg relative to reference of Glucophage SR 1000 mg Prolonged Release Tablets (Metformin Hydrochloride) in healthy male and female volunteers under fed conditionsCTRI/2019/04/018527Indoco Remedies Limited
已完成
不适用
Comparative bioavailability study of two test products of fixed dose combination capsule of ASA (acetylsalicylic acid) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) under fed conditionsCTRI/2013/06/003712Dushen J Chetty PhD24
尚未招募
不适用
Comparative bioavailability study of two different batches of Test products (Alogliptin and Pioglitazone tablets 12.5 mg/45 mg) compared with the reference product of (Oseni (alogliptin and pioglitazone) tablets 12.5 mg/ 45 mg), in healthy, adult, human subjects, under fasting conditions.CTRI/2019/04/018604Indoco Remedies Limited
尚未招募
不适用
A study of Thymoquinone tabletsCTRI/2020/12/029514Intas Pharmaceuticals Limited
尚未招募
Unknown
A Bioequivalence study of Azacitidine Tablets under Fasting Condition in Patients with Acute Myeloid Leukaemia in Remission Phase.CTRI/2023/06/054386Intas Pharmaceuticals Ltd., India